Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT Apr 13, 2022
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of… Feb 22, 2022
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of… Feb 9, 2022
Entheon Biomedical: Could DMT Be A Superior Psychedelic Treatment For Substance Use Disorder? Feb 4, 2022
